Sanne Schoffelen

This study generates glycoengineered recombinant alpha1-antitrypsin with in vitro and in vivo activities comparable to plasma-derived A1AT, offering a sustainable therapeutic alternative.

LeGenD predicts N-glycan structures and their abundance using lectin-binding patterns and AI, trained on glycoprofiles from recombinant proteins.

The paper investigates the phenotypic and transcriptional effects of glycoengineering in CHO cells, identifying distinct clusters and molecular mechanisms associated with different glycosyltransferase modifications.

This study shows that glycoengineering of HCV E2 glycoprotein affects antigen biochemical properties and immune response, with some glycans improving neutralization potency.

This study eliminates the Warburg Effect in mammalian cells by knocking out lactate dehydrogenase and feedback regulators, maintaining growth rate while reducing lactate production.

The paper identifies a relationship between protein structure and glycan structure, introducing a glycoimpact matrix to predict glycosylation patterns and validate it through disease variants and engineered antibodies.